Medical therapy of pituitary adenomas: Effects on tumor shrinkage

  • Annamaria Colao
  • Rosario Pivonello
  • Carolina Di Somma
  • Silvia Savastano
  • Ludovica F. S. Grasso
  • Gaetano Lombardi
Article
  • 301 Downloads

Abstract

The efficacy of dopamine-agonists (DA) in patients with prolactinomas and that of somatostatin analogues (SSA) in those with GH- and TSH-secreting adenomas is well established. More recently, data are accumulating suggesting a potential therapeutic role of DA also in patients with ACTH-secreting and clinically non-functioning (NFA) pituitary adenomas. This review aims at summarizing published results of DA and SSA on tumor shrinkage in patients with different histotypes of pituitary adenomas. Results of tumor shrinkage are of clinical relevance as tumor size is the one of the most important determinant of surgical outcome. While reduction of tumor size more than 50% of baseline size in macroprolactinomas treated with DA is a frequent finding in patients with GH-secreting adenomas treated with SSA tumor shrinkage only recently is becoming frequent thanks to the availability of depot formulations. Data on tumor shrinkage in patients with TSH-secreting adenomas treated with SSA are limited because of the rarity of these tumors. Very recently, DA have been reported of some efficacy also in patients with ACTH-secreting adenomas but data are still very limited. NFA respond very scantly to both DA and SSA even if receptors targeting these drugs are present. Whether this is due to limited receptor number or alterations of post-receptor pathway is still unknown.

Keywords

GH PRL ACTH TSH Pituitary tumors Somatostatin Dopamine 

References

  1. 1.
    Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534. doi:10.1210/er.2005-9998.PubMedGoogle Scholar
  2. 2.
    Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Acromegaly Treatment Consensus Workshop Participants, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054–8. doi:10.1210/jc.2002-011841.PubMedGoogle Scholar
  3. 3.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 2001;86:2849–53. doi:10.1210/jc.86.6.2849.PubMedGoogle Scholar
  4. 4.
    Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78:189–225.PubMedGoogle Scholar
  5. 5.
    Caccavelli L, Cussac D, Pellegrini I, Audinot V, Jaquet P, Enjalbert A. D2 dopaminergic receptors: normal and abnormal transduction mechanisms. Horm Res. 1992;38:78–83.PubMedGoogle Scholar
  6. 6.
    Giros B, Sokoloff P, Martres MP, Riou JF, Emorine LJ, Schwartz JC. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 1989;342:923–6. doi:10.1038/342923a0.PubMedGoogle Scholar
  7. 7.
    Spada A, Nicosia S, Cortelazzi L, Pezzo G, Bassetti M, Sartorio A, et al. In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide. J Clin Endocrinol Metab. 1983;56:1–10.PubMedGoogle Scholar
  8. 8.
    Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13:220–40. doi:10.1210/er.13.2.220.PubMedGoogle Scholar
  9. 9.
    Trouillas J, Chevallier P, Claustrat B, Hooghe-Peters E, Dubray C, Rousset B, et al. Inhibitory effects of the dopamine agonists quinagolide (CV 205–502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology. 1994;134:401–10. doi:10.1210/en.134.1.401.PubMedGoogle Scholar
  10. 10.
    Hofland LJ, Lamberts SWJ. Somatostatin receptor subtype expression in human tumors. Ann Oncol. 2001;12(Suppl 2):S31–6. doi:10.1023/A:1012420207244.PubMedGoogle Scholar
  11. 11.
    Culler MD, Taylor JE, Moreau JP. Somatostatin receptor subtypes: targeting functional and therapeutic specificity. Ann Endocrinol. 2002;63:2S5–2S12.Google Scholar
  12. 12.
    Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol. 2000;94:205–10.Google Scholar
  13. 13.
    Guillermet Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Physiology of somatostatin receptors. JEI 2005;28(11 Suppl International):5–9.Google Scholar
  14. 14.
    Garcıa de la Torre N, Wass JAH, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf). 2002;57:425–41. doi:10.1046/j.1365-2265.2002.01619.x.Google Scholar
  15. 15.
    Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitari adenomas. J Clin Endocrinol Metab. 2001;86:5194–200. doi:10.1210/jc.86.11.5194.PubMedGoogle Scholar
  16. 16.
    Thapar K, Kovacs KT, Stefaneanu L, Scheithauer BW, Horvath E, Lloyd RV, et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicentre randomized trial. Mayo Clin Proc. 1997;72:893–900.PubMedGoogle Scholar
  17. 17.
    Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab. 1994;79:113–8. doi:10.1210/jc.79.1.113.PubMedGoogle Scholar
  18. 18.
    Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs. 2002;11:787–800. doi:10.1517/13543784.11.6.787.PubMedGoogle Scholar
  19. 19.
    Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334:246–54. doi:10.1056/NEJM199601253340408.PubMedGoogle Scholar
  20. 20.
    Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87:3013–8. doi:10.1210/jc.87.7.3013.PubMedGoogle Scholar
  21. 21.
    Colao A, Marzullo P, Ferone D, Marinò V, Pivonello R, Di Somma C, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest. 1999;22:40–7.PubMedGoogle Scholar
  22. 22.
    Lancranjan I, Bruns C, Grass P, Jaquet P, Jarvell J, Kendall-Taylor P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996;45(Suppl 1):67–71. doi:10.1016/S0026-0495(96)90087-6.PubMedGoogle Scholar
  23. 23.
    McKeage K, Cheer A, Wagstaff AJ. Octreotide Long-Acting Release (LAR). A review of its use in the management of acromegaly. Drugs. 2003;63:2473–99. doi:10.2165/00003495-200363220-00014.PubMedGoogle Scholar
  24. 24.
    Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol. 2007;157(5):579–87. doi:10.1530/EJE-07-0383.PubMedGoogle Scholar
  25. 25.
    Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2006;64:209–14. doi:10.1111/j.1365-2265.2006.02450.x.Google Scholar
  26. 26.
    Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G, Arosio M, et al. Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogues naive patients with acromegaly. J Endocrinol Invest. 2008; In press.Google Scholar
  27. 27.
    Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707–16. doi:10.1530/eje.0.1460707.PubMedGoogle Scholar
  28. 28.
    van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM 230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004;89:638–45. doi:10.1210/jc.2003-031052.PubMedGoogle Scholar
  29. 29.
    Fedele M, De Martino I, Pivonello R, Ciarmiello A, Del Basso De Caro ML, Visone R, et al. SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas. Clin Cancer Res. 2007;13:2738–44. doi:10.1158/1078-0432.CCR-06-2505.PubMedGoogle Scholar
  30. 30.
    Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother. 2000;1:555–74. doi:10.1517/14656566.1.3.555.PubMedGoogle Scholar
  31. 31.
    Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518–22. doi:10.1210/jc.84.7.2518.PubMedGoogle Scholar
  32. 32.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82:3574–9. doi:10.1210/jc.82.11.3574.PubMedGoogle Scholar
  33. 33.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85:2247–52. doi:10.1210/jc.85.6.2247.PubMedGoogle Scholar
  34. 34.
    Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86:5256–61. doi:10.1210/jc.86.11.5256.PubMedGoogle Scholar
  35. 35.
    Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, Iervolino E, et al. Chronic treatment with CV 205–502 restores the gonadal function in hyperprolactinemia males. Eur J Endocrinol. 1996;135:548–52.PubMedGoogle Scholar
  36. 36.
    Vance ML, Lipper M, Klibanski A, Biller BM, Samaan NA, Molitch ME. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205–502. Ann Intern Med. 1990;112:668–73.PubMedGoogle Scholar
  37. 37.
    Cannavo S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest. 1999;22:306–9.PubMedGoogle Scholar
  38. 38.
    Cappabianca P, Lodrini S, Felisati G, Peca C, Cozzi R, Di Sarno A, et al. Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. J Endocrinol Invest. 2001;24:183–7.PubMedGoogle Scholar
  39. 39.
    Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349:2023–33. doi:10.1056/NEJMoa022657.PubMedGoogle Scholar
  40. 40.
    Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, et al. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol. 2008;158:595–603. doi:10.1530/EJE-07-0806.PubMedGoogle Scholar
  41. 41.
    Jaffe CA, Barkan AI. Acromegaly: recognition and treatment. Drugs. 1994;47:425–45.PubMedGoogle Scholar
  42. 42.
    Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 1997;82:518–23. doi:10.1210/jc.82.2.518.PubMedGoogle Scholar
  43. 43.
    Abs R, Versholst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83:374–8. doi:10.1210/jc.83.2.374.PubMedGoogle Scholar
  44. 44.
    Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol. 1998;139:516–21. doi:10.1530/eje.0.1390516.PubMedGoogle Scholar
  45. 45.
    Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, et al. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf). 1988;29:467–76. doi:10.1111/j.1365-2265.1988.tb03695.x.Google Scholar
  46. 46.
    Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemia and acromegalic patients. J Endocrinol Invest. 1997;20:537–46.PubMedGoogle Scholar
  47. 47.
    Rickels MR, Snyder PJ. Cabergoline decreases somatotroph adenoma size: a case report. Pituitary. 2004;7:107–10. doi:10.1007/s11102-005-5353-1.PubMedGoogle Scholar
  48. 48.
    Vilar L, Czepielewsk MA, Naves LA, Rollin GA, Casulari LA, Coelho CE. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract. 2007;13:396–402.PubMedGoogle Scholar
  49. 49.
    Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A, Lombardi G. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol. 2007;156(Suppl 1):S57–63. doi:10.1530/eje.1.02348.PubMedGoogle Scholar
  50. 50.
    Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:1856–63. doi:10.1210/jc.2004-1093.PubMedGoogle Scholar
  51. 51.
    Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:4405–10. doi:10.1210/jc.2004-2466.PubMedGoogle Scholar
  52. 52.
    Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006;91:2112–8. doi:10.1210/jc.2005-2110.PubMedGoogle Scholar
  53. 53.
    Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93:2957–68.PubMedGoogle Scholar
  54. 54.
    Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf). 2007;67:282–9. doi:10.1111/j.1365-2265.2007.02878.x.Google Scholar
  55. 55.
    Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397–403. doi:10.1210/jc.2005-2347.PubMedGoogle Scholar
  56. 56.
    Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol. 2007;157:579–87. doi:10.1530/EJE-07-0383.PubMedGoogle Scholar
  57. 57.
    Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab. 2007;92:1592–9. doi:10.1210/jc.2006-2084.PubMedGoogle Scholar
  58. 58.
    Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest. 2006;29:826–30.PubMedGoogle Scholar
  59. 59.
    Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol. 2005;153:187–93. doi:10.1530/eje.1.01968.PubMedGoogle Scholar
  60. 60.
    Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008;93:1412–7. doi:10.1210/jc.2007-1358.PubMedGoogle Scholar
  61. 61.
    Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumours. Endocr Rev. 1996;17:610–38. doi:10.1210/er.17.6.610.PubMedGoogle Scholar
  62. 62.
    Kienitz T, Quinkler M, Strasburger CJ, Ventz M. Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol. 2007;157:39–46. doi:10.1530/EJE-07-0098.PubMedGoogle Scholar
  63. 63.
    Warnet A, Lajeunie E, Gelbert F, Duet M, Chanson P, Cophignon J, et al. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201–995). Acta Endocrinol (Copenh). 1991;124:487–91.Google Scholar
  64. 64.
    Wemeau L, Dewailly D, Leroy R, D'Herbomez M, Mazzuca M, Decoulx M, et al. Long term treatment with a somatostatin analog SMS 201–995 in a patient with a thyrotropin and growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab. 1988;66:636–9.PubMedGoogle Scholar
  65. 65.
    Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 1996;81:3084–90. doi:10.1210/jc.81.8.3084.PubMedGoogle Scholar
  66. 66.
    Chanson P, Weintraub BD, Harris AG. Treatment of TSH-secreting pituitary adenomas with octreotide: a follow-up of 52 patients. Ann Intern Med. 1993;119:236–40.PubMedGoogle Scholar
  67. 67.
    Fischler MP, Reinhart WH. TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide. J Endocrinol Invest. 1999;22:64–5.PubMedGoogle Scholar
  68. 68.
    Colao A, Filippella M, Di Somma C, Manzi S, Rota F, Pivonello R, et al. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine. 2003;20:279–83. doi:10.1385/ENDO:20:3:279.PubMedGoogle Scholar
  69. 69.
    Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 1994;40:421–8.Google Scholar
  70. 70.
    Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000;85:1487–91. doi:10.1210/jc.85.4.1487.PubMedGoogle Scholar
  71. 71.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 2001;86:2849–53. doi:10.1210/jc.86.6.2849.PubMedGoogle Scholar
  72. 72.
    Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing’s syndrome. Endocrinol Metab Clin North Am. 2008;37:135–49. doi:10.1016/j.ecl.2007.10.010.PubMedGoogle Scholar
  73. 73.
    Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of ACTH-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454–62.PubMedGoogle Scholar
  74. 74.
    Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452–62. doi:10.1210/jc.2003-030837.PubMedGoogle Scholar
  75. 75.
    Pivonello R, Ferone D, de Herder WW, Faggiano A, Bodei L, de Krijger RR, et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab. 2007;92:65–9. doi:10.1210/jc.2006-0728.PubMedGoogle Scholar
  76. 76.
    Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab. 2004;89:4493–502. doi:10.1210/jc.2003-031746.PubMedGoogle Scholar
  77. 77.
    Miller JW, Crapo L. The medical treatment of Cushing’s syndrome. Endocr Rev. 1993;14:443–58. doi:10.1210/er.14.4.443.PubMedGoogle Scholar
  78. 78.
    Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline. J Endocrinol Invest. 1999;22:860–5.PubMedGoogle Scholar
  79. 79.
    Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152:645–54. doi:10.1530/eje.1.01876.PubMedGoogle Scholar
  80. 80.
    Boscaro M, Atkinson A, Bertherat J, et al. SOM230 Cushing’s disease study group. Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with Cushing’s disease. Presented at the 87th Annual Meeting of the Endocrine Society. San Diego (CA), June 4–7, 2005.Google Scholar
  81. 81.
    Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing’s syndrome. N Engl J Med. 2005;352:2457–8. doi:10.1056/NEJM200506093522322.PubMedGoogle Scholar
  82. 82.
    Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, et al. New medical approaches in pituitary adenomas. Horm Res. 2000;53(Suppl 3):76–87. doi:10.1159/000023539.PubMedGoogle Scholar
  83. 83.
    Bevan JS, Burke CW. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol (Oxf). 1986;25:561–72. doi:10.1111/j.1365-2265.1986.tb03610.x.Google Scholar
  84. 84.
    Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab. 2004;89:1674–83. doi:10.1210/jc.2003-030859.PubMedGoogle Scholar
  85. 85.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, et al. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab. 1998;83:248–52. doi:10.1210/jc.83.1.248.PubMedGoogle Scholar
  86. 86.
    Hedner P, Valdemarsson S. Reduced size of a hormonally silent pituitary adenoma during treatment with CV 205–502, a new dopamine agonist mainly stimulating D2 receptors. Neurosurgery. 1989;25:948–50. doi:10.1097/00006123-198912000-00015.PubMedGoogle Scholar
  87. 87.
    Kwekkboom DJ, Lamberts SWJ. Long-term treatment with dopamine agonist CV 205–502 of patients with clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma. Clin Endocrinol (Oxf). 1992;36:171–17. doi:10.1111/j.1365-2265.1992.tb00953.x.Google Scholar
  88. 88.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, et al. Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol (Oxf). 2000;52:437–45. doi:10.1046/j.1365-2265.2000.00951.x.Google Scholar
  89. 89.
    Ikuyama S, Nawata H, Kato K, Karashima T, Ibayashi H, Nakagaki H. Specific somatostatin receptors on human pituitary adenoma cell membranes. J Clin Endocrinol Metab. 1985;61:98–103.Google Scholar
  90. 90.
    Reubi JC, Heitz PU, Landolt AM. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab. 1987;65:65–73.PubMedCrossRefGoogle Scholar
  91. 91.
    Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab. 1994;78:398–403. doi:10.1210/jc.78.2.398.PubMedGoogle Scholar
  92. 92.
    Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, et al. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radio-iodinated analog of somatostatin. J Clin Endocrinol Metab. 1991;73:850–6. (123I)SDZ204–090.PubMedGoogle Scholar
  93. 93.
    Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 1994;79:1416–23. doi:10.1210/jc.79.5.1416.PubMedGoogle Scholar
  94. 94.
    Lamberts SWJ, de Herder WW, van der Lely AJ, Hofland LJ. Imaging and medical management of clinically nonfunctioning pituitary tumors. Endocrinologist. 1995;5:448–51. doi:10.1097/00019616-199511000-00020.Google Scholar
  95. 95.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, et al. Pituitary uptake of In-111-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. J Endocrinol Invest. 1999;22:176–83.PubMedGoogle Scholar
  96. 96.
    Borson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, et al. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin Endocrinol (Oxf). 1997;47:589–98. doi:10.1046/j.1365-2265.1997.3361119.x.Google Scholar
  97. 97.
    Warnet A, Harris AG, Renard E, Martin D, James-Deidier A, Chaumet-Riffaud P, and the French multicenter octreotide study group. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. Neurosurgery 1997;41:786–97. doi:10.1097/00006123-199710000-00005.PubMedGoogle Scholar
  98. 98.
    Gasperi M, Petrini L, Pilosu R, Nardi M, Marcello AA, Mastio F, et al. Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J Endocrinol Invest. 1993;16:541–3.PubMedGoogle Scholar
  99. 99.
    De Bruin TWA, Kwekkeboom DJ, van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW, Croughs RJ. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab. 1992;75:1310–7.PubMedGoogle Scholar
  100. 100.
    Klibanski A, Alexander JM, Bikkal HA, Hsu DW, Swearingen B, Zervas NT. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. J Clin Endocrinol Metab. 1991;73:1248–55.PubMedGoogle Scholar
  101. 101.
    Katznelson L, Oppenheim DS, Coughlin JF, Kliman B, Schoenfeld DA, Klibanski A. Chronic somatostatin analog administration in patients with a-subunit-secreting pituitary tumors. J Clin Endocrinol Metab. 1992;75:1318–25. doi:10.1210/jc.75.5.1318.PubMedGoogle Scholar
  102. 102.
    Andersen M, Bjerre P, Schrøder HD, Edal A, Høilund-Carlsen PF, Pedersen PH, et al. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf). 2001;54:23–30. doi:10.1046/j.1365-2265.2001.01172.x.Google Scholar
  103. 103.
    Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E, A.L.I.C.E. Study Group. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 2006;29:1017–20.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Annamaria Colao
    • 1
  • Rosario Pivonello
    • 1
  • Carolina Di Somma
    • 1
  • Silvia Savastano
    • 1
  • Ludovica F. S. Grasso
    • 1
  • Gaetano Lombardi
    • 1
  1. 1.Department of Molecular & Clinical Endocrinology and Oncology“Federico II” University of NaplesNaplesItaly

Personalised recommendations